Related Experiment Videos
Recombinant human granulocyte-macrophage colony-stimulating factor as treatment for chronic leg ulcers
J R Borbolla-Escoboza1, R María-Aceves, M A López-Hernández
1Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, México DF. jrborbolla@infosel.net.mx
Insights
A single dose of recombinant human granulocyte-macrophage colony stimulating factor (rHGM-CSF) effectively healed 80% of chronic leg ulcers in a small study. This treatment demonstrated safety and efficacy for chronic wound management.
Area of Science:
- Wound healing research
- Regenerative medicine
- Dermatology
Background:
- Chronic leg ulcers represent a significant clinical challenge with limited effective treatment options.
- Recombinant human granulocyte-macrophage colony stimulating factor (rHGM-CSF) is a growth factor with potential roles in tissue repair and inflammation modulation.
Purpose of the Study:
- To assess the safety and efficacy of a single subcutaneous perilesional injection of 300 micrograms of rHGM-CSF.
- To evaluate rHGM-CSF as a treatment for chronic leg ulcers.
Main Methods:
- Prospective, descriptive study conducted in an outpatient setting.
- Involved 10 patients diagnosed with chronic leg ulcers.
- Monitored ulcer diameter and observed for any adverse side effects over a 4-week period.
Main Results:
- Significant healing observed in 8 out of 10 treated chronic leg ulcers within 4 weeks.
- The remaining two ulcers showed a mean diameter reduction of 21%.
- The sole reported side effect was mild perilesional pain in one patient, which resolved with paracetamol.
Conclusions:
- A single perilesional subcutaneous administration of rHGM-CSF is a safe and effective therapeutic approach for chronic leg ulcers.
- rHGM-CSF shows promise as a novel treatment modality for improving chronic wound healing outcomes.
Objective:
To evaluate the safety and effectiveness of a single subcutaneous perilesional administration of 300 micrograms of recombinant human granulocyte-macrophage colony stimulating factor (rHGM-CSF) for the treatment of chronic leg ulcers.
Design:
Prospective, descriptive evaluation in an outpatient group.
Setting:
The Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City.
Patients:
10 patients with chronic leg ulcers.
Measurements:
Ulcer diameter and side effects.
Results:
After 4 weeks observation, 8 of the 10 ulcers had healed; the other two had a mean diameter decrease of 21%. The only side effect was found in a 58 year old female who complained of moderate perilesional pain two days after having received treatment: it was successfully treated with paracetamol.
Conclusion:
We believe that a single perilesional subcutaneous administration of rhGM-CSF is safe and effective for the treatment of chronic leg ulcers.